---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-003090"
form_type: "8-K"
ticker: "SNOA"
cik: "0001367083"
company_name: "Sonoma Pharmaceuticals, Inc."
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T06:05:14.520276+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# Sonoma Pharmaceuticals files updated investor presentation; no material new information disclosed

## Summary
- Filed Form 8-K with Item 7.01 disclosure attaching an updated investor presentation dated May 10, 2023.
- Presentation covers Sonoma's stabilized hypochlorous acid (HOCl) products for dermatology, wound care, and other applications.
- Company sells products directly or via partners in 55 countries; no specific financial results or guidance provided.
- No changes in leadership, M&A, debt, litigation, or regulatory actions reported.
- Forward-looking statements include risks typical of the business; no new material facts for investors.

## SEC filing metadata
- accession: 0001683168-23-003090
- form_type: 8-K
- ticker: SNOA
- cik: 0001367083
- company_name: Sonoma Pharmaceuticals, Inc.
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367083/000168316823003090/0001683168-23-003090-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367083/000168316823003090/sonoma_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-003090
- JSON: https://secwatch.observer/filing/0001683168-23-003090.json
- Plain text: https://secwatch.observer/filing/0001683168-23-003090.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.